Literature DB >> 8472744

Isradipine attenuates the ischemia-induced release of dopamine in the striatum of the rat.

H Ooboshi1, S Sadoshima, S Ibayashi, H Yao, H Uchimura, M Fujishima.   

Abstract

We examined the effect of isradipine, a blocker of L-type voltage-sensitive Ca2+ channels (VSCCs), on the ischemia-induced release of dopamine in the rat striatum. Perfusion of 200 micrograms/ml isradipine in the striatum did not alter extracellular dopamine concentrations monitored by microdialysis. However, a marked increase (145-fold) in dopamine level during forebrain ischemia, developed by bilateral carotid artery occlusion, was attenuated significantly by 37% by isradipine whereas the intensity of ischemia, monitored by striatal blood flow, was unchanged. These results suggest that isradipine attenuates the ischemia-induced release of dopamine via blockade of L-type VSCCs on dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472744     DOI: 10.1016/0014-2999(93)90363-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Calcium antagonist isradipine reduces metabolic alterations in acute cerebral ischemia in spontaneously hypertensive rats.

Authors:  S Ibayashi; T Nagao; T Kitazono; H Ooboshi; J Kitayama; S Sadoshima; M Fujishima
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 2.  Fibromyalgia syndrome: a pain modulation disorder related to altered limbic function?

Authors:  J A Goldstein
Journal:  Baillieres Clin Rheumatol       Date:  1994-11

3.  Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Kyota Fujita; Toshihiro Seike; Noriko Yutsudo; Mizuki Ohno; Hidetaka Yamada; Hiroo Yamaguchi; Kunihiko Sakumi; Yukiko Yamakawa; Mizuho A Kido; Atsushi Takaki; Toshihiko Katafuchi; Yoshinori Tanaka; Yusaku Nakabeppu; Mami Noda
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.